{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:29:58Z","timestamp":1790958598368,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1208\/s12249-021-02099-3","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T18:02:39Z","timestamp":1628791359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Eudragit S-100 Surface Engineered Nanostructured Lipid Carriers for Colon Targeting of 5-Fluorouracil: Optimization and In Vitro and In Vivo Characterization"],"prefix":"10.1208","volume":"22","author":[{"given":"Kruti","family":"Borderwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Rathod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarita","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavin","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"2099_CR1","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1200\/JCO.2003.11.045","volume":"21","author":"RK Ramanathan","year":"2003","unstructured":"Ramanathan RK, Clark JW, Kemeny NE, Lenz H-J, Gococo KO, Haller DG, et al. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. J Clin Oncol. 2003;21:2904\u201311.","journal-title":"J Clin Oncol"},{"key":"2099_CR2","first-page":"1112","volume":"2","author":"SC Dhawale","year":"2010","unstructured":"Dhawale SC, Bankar AS, Patro MN. Formulation and evaluation porous microspheres of 5-fluorouracil for colon targeting. Int J Pharm Tech Res. 2010;2:1112\u20138.","journal-title":"Int J Pharm Tech Res"},{"key":"2099_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11051-013-1893-x","volume":"15","author":"R Khatik","year":"2013","unstructured":"Khatik R, Mishra R, Verma A, Dwivedi P, Kumar V, Gupta V, et al. Colon-specific delivery of curcumin by exploiting Eudragit-decorated chitosan nanoparticles in vitro and in vivo. J Nanopart Res. 2013;15:1\u201315.","journal-title":"J Nanopart Res"},{"key":"2099_CR4","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.3109\/10717544.2015.1084400","volume":"23","author":"S Tummala","year":"2016","unstructured":"Tummala S, Gowthamarajan K, Satish Kumar MN, Wadhwani A. Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors. Drug Deliv. 2016;23:1773\u201387.","journal-title":"Drug Deliv"},{"key":"2099_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejpb.2004.09.005","volume":"59","author":"A Lamprecht","year":"2005","unstructured":"Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. Observations in simultaneous microencapsulation of 5-fluorouracil and leucovorin for combined pH-dependent release. Eur J Pharm Biopharm. 2005;59:367\u201371.","journal-title":"Eur J Pharm Biopharm"},{"key":"2099_CR6","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3390\/molecules13102340","volume":"13","author":"JL Arias","year":"2008","unstructured":"Arias JL. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules. 2008;13:2340\u201369.","journal-title":"Molecules."},{"key":"2099_CR7","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1016\/j.biomaterials.2007.05.026","volume":"28","author":"Y Dong","year":"2007","unstructured":"Dong Y, Feng S-S. In vitro and in vivo evaluation of methoxy polyethylene glycol\u2013polylactide (MPEG\u2013PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials. 2007;28:4154\u201360.","journal-title":"Biomaterials."},{"key":"2099_CR8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang N, Yin Y, Xu S-J, Chen W-S. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551\u201369.","journal-title":"Molecules."},{"key":"2099_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0378-5173(02)00344-7","volume":"245","author":"N Shimono","year":"2002","unstructured":"Shimono N, Takatori T, Ueda M, Mori M, Higashi Y, Nakamura Y. Chitosan dispersed system for colon-specific drug delivery. Int J Pharm. 2002;245:45\u201354.","journal-title":"Int J Pharm"},{"key":"2099_CR10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3109\/10717544.2014.916768","volume":"23","author":"J Zhang","year":"2016","unstructured":"Zhang J, Wang X, Liu T, Liu S, Jing X. Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer. Drug Deliv. 2016;23:784\u201390.","journal-title":"Drug Deliv"},{"key":"2099_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3109\/02652048.2014.944947","volume":"32","author":"P Li","year":"2015","unstructured":"Li P, Yang Z, Wang Y, Peng Z, Li S, Kong L, et al. Microencapsulation of coupled folate and chitosan nanoparticles for targeted delivery of combination drugs to colon. J Microencapsul. 2015;32:40\u20135.","journal-title":"J Microencapsul"},{"key":"2099_CR12","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/pgs.13.54","volume":"14","author":"AB van Kuilenburg","year":"2013","unstructured":"van Kuilenburg AB, Maring JG. Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients. Pharmacogenomics. 2013;14:799\u2013811.","journal-title":"Pharmacogenomics."},{"key":"2099_CR13","first-page":"3983","volume":"26","author":"Y Nakayama","year":"2006","unstructured":"Nakayama Y, Matsumoto K, Inoue Y, Katsuki T, Kadowaki K, Shibao K, et al. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs. Anticancer Res. 2006;26:3983\u20138.","journal-title":"Anticancer Res"},{"key":"2099_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3109\/10717544.2014.913733","volume":"23","author":"G Rai","year":"2016","unstructured":"Rai G, Yadav AK, Jain NK, Agrawal GP. Eudragit-coated dextran microspheres of 5-fluorouracil for site-specific delivery to colon. Drug Deliv. 2016;23:328\u201337.","journal-title":"Drug Deliv"},{"key":"2099_CR15","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3390\/ma8030832","volume":"8","author":"MB Subudhi","year":"2015","unstructured":"Subudhi MB, Jain A, Jain A, Hurkat P, Shilpi S, Gulbake A, et al. Eudragit S100 coated citrus pectin nanoparticles for colon targeting of 5-fluorouracil. Materials (Basel). 2015;8:832\u201349.","journal-title":"Materials (Basel)"},{"key":"2099_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejpb.2014.05.019","volume":"88","author":"A Patil-Gadhe","year":"2014","unstructured":"Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur J Pharm Biopharm. 2014;88:160\u20138.","journal-title":"Eur J Pharm Biopharm"},{"key":"2099_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jsps.2014.11.010","volume":"23","author":"S Tummala","year":"2015","unstructured":"Tummala S, Kumar MNS, Prakash A. Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer. Saudi Pharm J. 2015;23:308\u201314.","journal-title":"Saudi Pharm J"},{"issue":"2","key":"2099_CR18","first-page":"52","volume":"1","author":"PS Sutar","year":"2013","unstructured":"Sutar PS, Joshi VJ. Preparation and characterisation of 5-fluorouracil loaded PLGA nanoparticles for colorectal cancer therapy. Unique J Pharm Biol Sci. 2013;1(2):52\u20138.","journal-title":"Unique J Pharm Biol Sci"},{"key":"2099_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3109\/08982104.2012.662653","volume":"22","author":"J Varshosaz","year":"2012","unstructured":"Varshosaz J, Hassanzadeh F, Sadeghi H, Khadem M. Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma. J Liposome Res. 2012;22:224\u201336.","journal-title":"J Liposome Res"},{"key":"2099_CR20","first-page":"3911","volume":"10","author":"C-Y Qu","year":"2015","unstructured":"Qu C-Y, Zhou M, Chen Y, Chen M, Shen F, Xu L-M. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. Int J Nanomedicine. 2015;10:3911\u201320.","journal-title":"Int J Nanomedicine"},{"key":"2099_CR21","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.2147\/IJN.S117511","volume":"11","author":"PS Rajinikanth","year":"2016","unstructured":"Rajinikanth PS, Chellian J. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomedicine. 2016;11:5067\u201377.","journal-title":"Int J Nanomedicine"},{"key":"2099_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.colsurfb.2013.10.018","volume":"114","author":"J Luan","year":"2014","unstructured":"Luan J, Zhang D, Hao L, Qi L, Liu X, Guo H, et al. Preparation, characterization and pharmacokinetics of Amoitone B-loaded long circulating nanostructured lipid carriers. Colloids Surf B: Biointerfaces. 2014;114:255\u201360.","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"2099_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/2277-9175.100147","volume":"1","author":"S Andalib","year":"2012","unstructured":"Andalib S, Varshosaz J, Hassanzadeh F, Sadeghi H. Optimization of LDL targeted nanostructured lipid carriers of 5-FU by a full factorial design. Adv Biomed Res. 2012;1:45.","journal-title":"Adv Biomed Res"},{"key":"2099_CR24","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.2147\/IJN.S215835","volume":"14","author":"MH Kim","year":"2019","unstructured":"Kim MH, Kim KT, Sohn SY, Lee JY, Lee CH, Yang H, et al. Formulation and evaluation of nanostructured lipid carriers (NLCs) of 20(S)-protopanaxadiol (PPD) by Box-Behnken design. Int J Nanomedicine. 2019;14:8509\u201320.","journal-title":"Int J Nanomedicine"},{"key":"2099_CR25","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s13346-020-00839-9","volume":"11","author":"P Shah","year":"2021","unstructured":"Shah P, Chavda K, Vyas B, Patel S. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. Drug Deliv and Transl Res. 2021;11:1166\u201385.","journal-title":"Drug Deliv and Transl Res"},{"issue":"3","key":"2099_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/10837450.2010.542163","volume":"17","author":"KW Kasongo","year":"2012","unstructured":"Kasongo KW, M\u00fcller RH, Walker RB. The use of hot and cold high pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients. Pharm Dev Technol. 2012;17(3):353\u201362.","journal-title":"Pharm Dev Technol"},{"key":"2099_CR27","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3390\/pr8121579","volume":"8","author":"WA Mahdi","year":"2020","unstructured":"Mahdi WA, Hussain A, Ramzan M. 5-Fluorouracil loaded biogenic and albumin capped gold nanoparticles using bacterial enzyme\u2014in vitro-in silico Gastroplus\u00ae simulation and prediction. Processes. 2020;8:1579.","journal-title":"Processes."},{"issue":"4","key":"2099_CR28","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/2210681209666181226153741","volume":"10","author":"M Lalan","year":"2020","unstructured":"Lalan M, Shah P, Shah K, Prasad A. Developmental studies of curcumin NLCs as safe alternative in management of infectious childhood dermatitis. Nanoscience & Nanotechnology-Asia. 2020;10(4):390\u2013403.","journal-title":"Nanoscience & Nanotechnology-Asia"},{"issue":"1","key":"2099_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/21691401.2021.1939709","volume":"49","author":"P Shah","year":"2021","unstructured":"Shah P, Dubey P, Vyas B, Kaul A, Mishra AK, Chopra D, et al. Lamotrigine loaded PLGA nanoparticles intended for direct nose to brain delivery in epilepsy: pharmacokinetic, pharmacodynamic and scintigraphy study. Artificial Cells, Nanomedicine, and Biotechnology. 2021;49(1):511\u201322.","journal-title":"Artificial Cells, Nanomedicine, and Biotechnology"},{"key":"2099_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.7897\/2230-8407.0811216","volume":"8","author":"B Naik","year":"2017","unstructured":"Naik B, Gandhi J, Shah P, Naik H, Sarolia J. Asenapine maleate loaded solid lipid nanoparticles for oral delivery. International Research Journal of Pharmacy. 2017;8:45\u201353.","journal-title":"International Research Journal of Pharmacy"},{"key":"2099_CR31","doi-asserted-by":"publisher","unstructured":"Shah P, Sarolia J, Vyas B, Wagh P, Kaul A, Mishra AK. PLGA Nanoparticles for nose to brain delivery of clonazepam: formulation, optimization by 32 factorial design, In vitro and In vivo Evaluation. Curr Drug Deliv. 2021;17. https:\/\/doi.org\/10.2174\/1567201817666200708115627.","DOI":"10.2174\/1567201817666200708115627"},{"issue":"4","key":"2099_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2174\/2210681209666190218143736","volume":"10","author":"K Borderwala","year":"2020","unstructured":"Borderwala K, Swain G, Mange N, Gandhi J, Lalan M, Singhvi G, et al. Optimization of solid lipid nanoparticles of ezetimibe in combination with simvastatin using quality by design (QbD). Nanoscience & Nanotechnology-Asia. 2020;10(4):404\u201318.","journal-title":"Nanoscience & Nanotechnology-Asia"},{"key":"2099_CR33","doi-asserted-by":"publisher","unstructured":"Mahdi ZS, Roshan FT, Nikzad M, Ezoji H. Biosynthesis of zinc oxide nanoparticles using bacteria: a study on the characterization and application for electrochemical determination of bisphenol A. Inorg Nano-Met Chem. 2020:1\u20139. https:\/\/doi.org\/10.1080\/24701556.2020.1835962.","DOI":"10.1080\/24701556.2020.1835962"},{"issue":"3","key":"2099_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jsps.2009.08.006","volume":"17","author":"M El-Badry","year":"2009","unstructured":"El-Badry M, Fetih G, Fathy M. Improvement of solubility and dissolution rate of indomethacin by solid dispersions in Gelucire 50\/13 and PEG4000. Saudi Pharmaceutical Journal. 2009;17(3):217\u201325.","journal-title":"Saudi Pharmaceutical Journal"},{"issue":"1-2","key":"2099_CR35","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijpharm.2007.12.037","volume":"356","author":"A Bayat","year":"2008","unstructured":"Bayat A, Dorkoosh FA, Dehpour AR, Moezi L, Larijani B, Junginger HE, et al. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm. 2008;356(1-2):259\u201366.","journal-title":"Int J Pharm"},{"key":"2099_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3797\/scipharm.0908-09","volume":"78","author":"V Dash","year":"2010","unstructured":"Dash V, Mishra SK, Singh M, Goyal AK, Rath G. Release kinetic studies of aspirin microcapsules from ethyl cellulose, cellulose acetate phthalate and their mixtures by emulsion solvent evaporation method. Sci Pharm. 2010;78:93\u2013102.","journal-title":"Sci Pharm"},{"issue":"6","key":"2099_CR37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4103\/0250-474X.59544","volume":"71","author":"VR Sinha","year":"2009","unstructured":"Sinha VR, Kumar RV, Bhinge JR. A stability-indicating RP-HPLC assay method for 5-fluorouracil. Indian J Pharm Sci. 2009;71(6):630\u20137.","journal-title":"Indian J Pharm Sci"},{"issue":"11","key":"2099_CR38","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1016\/j.xphs.2018.07.021","volume":"107","author":"T Alam","year":"2018","unstructured":"Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Adaptation of quality by design based development of isradipine nanostructured\u2013lipid carrier and its evaluation for in vitro gut permeation and in vivo solubilization fate. J Pharm Sci. 2018;107(11):2914\u201326.","journal-title":"J Pharm Sci"},{"issue":"4","key":"2099_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2174\/1567201817666201026111559","volume":"18","author":"BK Pathak","year":"2021","unstructured":"Pathak BK, Raghav M, Thakkar AR, Vyas BA, Shah PJ. Enhanced oral bioavailability of etodolac by the liquisolid compact technique: optimisation, in-vitro and in-vivo evaluation. Current Drug Delivery. 2021;18(4):471\u201386.","journal-title":"Current Drug Delivery"},{"issue":"1-2","key":"2099_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ijpharm.2010.09.007","volume":"401","author":"Y Agrawal","year":"2010","unstructured":"Agrawal Y, Petkar KC, Sawant KK. Development, evaluation and clinical studies of Acitretin loaded nanostructured lipid carriers for topical treatment of psoriasis. Int J Pharm. 2010;401(1-2):93\u2013102.","journal-title":"Int J Pharm"},{"issue":"3","key":"2099_CR41","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jare.2016.03.002","volume":"7","author":"NV Shah","year":"2016","unstructured":"Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J Adv Res. 2016;7(3):423\u201334.","journal-title":"J Adv Res"},{"issue":"2","key":"2099_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.nano.2011.06.004","volume":"8","author":"A Ahad","year":"2012","unstructured":"Ahad A, Aqil A, Kohli K, Sultana Y, Mujeeb M, Ali A. Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan. Nanomedicine. 2012;8(2):237\u201349.","journal-title":"Nanomedicine"},{"key":"2099_CR43","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2147\/IJN.S195048","volume":"14","author":"MK Anwer","year":"2019","unstructured":"Anwer MK, Mohammad M, Ezzeldin E, Fatima F, Alalaiwe A, Iqbal M. Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats. Int J Nanomedicine. 2019;14:1587\u201395.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"2099_CR44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1248\/cpb.59.272","volume":"59","author":"RC Nagarwal","year":"2011","unstructured":"Nagarwal RC, Singh PN, Kant S, Maiti P, Pandit JK. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study. Chem Pharm Bull (Tokyo). 2011;59(2):272\u20138.","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"2099_CR45","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013007706","volume":"30","author":"VK Sharma","year":"2013","unstructured":"Sharma VK, Jain A, Soni V. Nano-aggregates: emerging delivery tools for tumor therapy. Crit Rev Ther Drug Carrier Syst. 2013;30:535\u201363.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"3","key":"2099_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13346-016-0291-1","volume":"6","author":"U Nagaich","year":"2016","unstructured":"Nagaich U, Gulati N. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: design and in vivo characterization. Drug Deliv Transl Res. 2016;6(3):289\u201398.","journal-title":"Drug Deliv Transl Res"},{"key":"2099_CR47","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/BF02976689","volume":"26","author":"H Zhang","year":"2003","unstructured":"Zhang H, Yao M, Morrison RA, Chong S. Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res. 2003;26:768\u201372.","journal-title":"Arch Pharm Res"},{"issue":"3","key":"2099_CR48","first-page":"219","volume":"4","author":"R Mohammadzadeh","year":"2014","unstructured":"Mohammadzadeh R, Baradaran B, Valizadeh H, Yousefi B, Zakeri-Milani P. Reduced ABCB1 expression and activity in the presence of acrylic copolymers. Adv Pharm Bull. 2014;4(3):219\u201324.","journal-title":"Adv Pharm Bull"},{"issue":"2","key":"2099_CR49","first-page":"121","volume":"61","author":"H Wei","year":"2007","unstructured":"Wei H, Qing D, De-Ying C, Bai X. Fanli-Fang. Pectin\/ethylcellulose as film coatings for colon-specific drug delivery: preparation and in vitro evaluation using 5-fluorouracil pellets. PDA J Pharm Sci Technol. 2007;61(2):121\u201330.","journal-title":"PDA J Pharm Sci Technol"},{"issue":"1-2","key":"2099_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ijpharm.2016.11.012","volume":"516","author":"MM El-Hammadi","year":"2017","unstructured":"El-Hammadi MM, Delgado \u00c1V, Melguizo C, Prados JC, Arias JL. Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. Int J Pharm. 2017;516(1-2):61\u201370.","journal-title":"Int J Pharm"},{"issue":"2","key":"2099_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jconrel.2012.12.021","volume":"166","author":"A Beloqui","year":"2013","unstructured":"Beloqui A, Solin\u00eds MA, Gasc\u00f3n AR, del Pozo-Rodr\u00edguez A, des Rieux A, Pr\u00e9at V. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J Control Release. 2013;166(2):115\u201323.","journal-title":"J Control Release"},{"issue":"8","key":"2099_CR52","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1248\/bpb.21.871","volume":"21","author":"J Gu","year":"1998","unstructured":"Gu J, Yuasa H, Hayashi Y, Watanabe J. First-pass metabolism of 5-fluorouracil in the perfused rat small intestine. Biol Pharm Bull. 1998;21(8):871\u20133.","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"2099_CR53","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/10717544.2017.1337823","volume":"24","author":"M Elmowafy","year":"2017","unstructured":"Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Deliv. 2017;24(1):932\u201341.","journal-title":"Drug Deliv"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02099-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-021-02099-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-02099-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T15:26:45Z","timestamp":1630423605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-021-02099-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2099"],"URL":"https:\/\/doi.org\/10.1208\/s12249-021-02099-3","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"26 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"216"}}